These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6683998)

  • 1. Lack of activity of cyclophosphamide in ovarian cancer patients refractory to cis-dichlorodiammine platinum.
    Sessa C; D'Incalci M; Colombo N; Pecorelli G; Mangioni C
    Cancer Chemother Pharmacol; 1983; 11(1):33-4. PubMed ID: 6683998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cis-dichlorodiammine platinum (II) in advanced ovarian carcinoma.
    Stewart JF; Tattersall MH; Woods RL; Fox RM
    Med J Aust; 1979 Jun; 1(12):548-50. PubMed ID: 470725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma.
    Carmo-Pereira J; Costa FO; Henriques E
    Cancer Chemother Pharmacol; 1983; 10(2):100-3. PubMed ID: 6403254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
    Cantù MG; Buda A; Parma G; Rossi R; Floriani I; Bonazzi C; Dell'Anna T; Torri V; Colombo N
    J Clin Oncol; 2002 Mar; 20(5):1232-7. PubMed ID: 11870165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
    Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
    J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced ovarian cancer with cis-dichlorodiammine platinum in combination with cyclophosphamide. An E.C.O.G. pilot study.
    Israel L; Aguilera J; Breau JL
    Am J Clin Oncol; 1983 Feb; 6(1):85-9. PubMed ID: 6682285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of intraperitoneal interferon-alpha 2b and intravenous cis-platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group pilot study.
    Moore DH; Valea F; Walton LA; Soper J; Clarke-Pearson D; Fowler WC
    Gynecol Oncol; 1995 Nov; 59(2):267-72. PubMed ID: 7590485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.
    Di Re F; Bohm S; Oriana S; Spatti GB; Zunino F
    Cancer Chemother Pharmacol; 1990; 25(5):355-60. PubMed ID: 2306797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral cyclophosphamide in recurrent ovarian cancer.
    Handolias D; Quinn M; Foo S; Mileshkin L; Grant P; Dutu G; Rischin D
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e154-60. PubMed ID: 23718870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer.
    Young RC; Von Hoff DD; Gormley P; Makuch R; Cassidy J; Howser D; Bull JM
    Cancer Treat Rep; 1979; 63(9-10):1539-44. PubMed ID: 387224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A pilot trial of high dose CEP (cyclophosphamide, epirubicin, cis-platinum) therapy in patients with advanced and recurrent ovarian cancer].
    Hiura M; Ogawa M; Nozawa S; Kudo R; Kuwabara Y; Takahashi T; Takayama M; Tateno M; Ohashi Y; Yakushiji M
    Gan To Kagaku Ryoho; 2000 Apr; 27(4):585-91. PubMed ID: 10791001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
    Soulié P; Bensmaïne A; Garrino C; Chollet P; Brain E; Fereres M; Jasmin C; Musset M; Misset JL; Cvitkovic E
    Eur J Cancer; 1997 Aug; 33(9):1400-6. PubMed ID: 9337681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-agent cis-platinum therapy for advanced ovarian cancer.
    Gershenson DM; Wharton JT; Herson J; Edwards CL; Rutledge FN
    Obstet Gynecol; 1981 Oct; 58(4):487-96. PubMed ID: 7024883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of high-dose epirubicin in platinum-pretreated patients with ovarian carcinoma.
    Vermorken JB; ten Bokkel Huinink WW; Kobierska A; van der Burg ME; Forni M; Piccart MJ; van der Putten E
    Oncology; 1999 Jul; 57(1):10-6. PubMed ID: 10394119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cis-platinum in the treatment of advanced or recurrent adenocarcinoma of the ovary. A phase II study of the Gynecologic Oncology Group.
    Thigpen JT; Lagasse L; Homesley H; Blessing JA
    Am J Clin Oncol; 1983 Aug; 6(4):431-5. PubMed ID: 6683465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; Olt G; Lentz SS; Bell J
    Gynecol Oncol; 2003 Sep; 90(3):581-6. PubMed ID: 13678728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moderate-dose cyclophosphamide for disseminated ovarian carcinoma: a phase II study.
    Carmo-Pereira J; Costa FO; Henriques E
    Eur J Cancer Clin Oncol; 1983 Apr; 19(4):461-5. PubMed ID: 6683184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cyclophosphamide followed by cisplatinum in the treatment of ovarian cancer.
    Osborne R; Evans B; Gallagher C; Wood C; Slevin M; Shepherd J; Wiltshaw E
    Cancer Chemother Pharmacol; 1987; 20(1):48-52. PubMed ID: 3621453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical trial of cisplatin in the treatment of ovarian carcinoma].
    Yoshizawa H; Kanazawa K; Takeuchi S; Okamura Y; Goto S; Kajiwara T
    Gan To Kagaku Ryoho; 1982 May; 9(5):822-30. PubMed ID: 6764112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.